Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (25 quarters reported)
$369M in Q3 2013 → — now. Hover for any quarter.
As reported for the quarter ended June 30, 2023. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| C Confidential | NaN% | Unchanged | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2023 · filed August 15, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| GH Gelesis Hldgs Inc | Exited | −12,056,626 | −$1.97M | — |
quarter ended March 31, 2023 · filed May 15, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| GH Gelesis Hldgs Inc | New | +12,056,626 | +$1.97M | 100.0% |
quarter ended March 31, 2019 · filed May 15, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Celldex Therapeutics, Inc. | Exited | −6,865,000 | −$1.36M | — |
quarter ended December 31, 2018 · filed February 13, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| C Confidential | New | +0 | — | — |
quarter ended September 30, 2018 · filed November 13, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Celldex Therapeutics, Inc. | Trimmed | −6 | −$3 | 100.0% |
| C Confidential | Exited | +0 | — | — |
quarter ended June 30, 2018 · filed August 10, 2018
No position changes this quarter.
quarter ended March 31, 2018 · filed May 10, 2018
No position changes this quarter.
quarter ended December 31, 2017 · filed February 12, 2018
No position changes this quarter.
Loading...
